OncoSil™ has been studied in combination with standard-of-care chemotherapy for the treatment of patients with unresectable locally advanced pancreatic cancer in two active clinical trials. Both trials are now closed to recruitment.
A single-arm open-label pilot study of OncoSil™ in patients treated with FOLFIRINOX or gemcitabine + nab-paclitaxel chemotherapy.
Conducted in Australia, the United Kingdom and Belgium.
For more details of the PanCO study visit ClinicalTrials.gov
A single-arm open-label pilot study of OncoSil™ in patients treated with gemcitabine ± nab-paclitaxel chemotherapy.
Conducted in the United States of America.
For more details of the OncoPaC-1 study visit ClinicalTrials.gov